Dynavax Technologies
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 408
- Market Cap
- $1.4B
- Introduction
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults
- Conditions
- ShinglesVaccine-Preventable DiseasesHerpes Zoster
- Interventions
- Biological: Z-1018Biological: Shingrix
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 440
- Registration Number
- NCT06569823
- Locations
- 🇦🇺
Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
- Conditions
- PlagueVaccine-Preventable DiseasesPlague, Pneumonic
- Interventions
- Biological: rF1V vaccineBiological: rF1V vaccine and CpG 1018® adjuvant
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 200
- Registration Number
- NCT05506969
- Locations
- 🇺🇸
Optimal Research Alabama, Huntsville, Alabama, United States
🇺🇸Optimal Research California, San Diego, California, United States
🇺🇸Optimal Research Florida, Melbourne, Florida, United States
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers
- Conditions
- ShinglesVaccine-Preventable DiseasesHerpes Zoster
- Interventions
- Biological: Z-1018Biological: Shingrix
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT05245838
- Locations
- 🇦🇺
Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia
🇦🇺Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
🇦🇺Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
- Conditions
- End Stage Renal Disease on Hemodialysis (Diagnosis)
- Interventions
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 119
- Registration Number
- NCT03934736
- Locations
- 🇺🇸
DaVita Clinical Research or Affiliate, Milwaukee, Wisconsin, United States
DV2-HBV-27: Observational Pregnancy Registry
- Conditions
- Pregnant
- Interventions
- Biological: HEPLISAV-B
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT03664648
- Locations
- 🇺🇸
PPD Registry Office, Recruiting Nationwide, Wilmington, North Carolina, United States
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT03326752
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸Ronald Reagan University of California Los Angeles Medical Center, Santa Monica, California, United States
🇺🇸Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Metastatic MelanomaHead Neck Cancer
- Interventions
- Drug: SD-101(1)Drug: SD-101(2)Biological: SD-101(3)Biological: Pembrolizumab
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 241
- Registration Number
- NCT02521870
- Locations
- 🇺🇸
University of Alabama School of Medicine, Birmingham, Alabama, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT02266147
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
- Conditions
- Healthy
- Interventions
- Biological: HEPLISAVBiological: Engerix-B
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 8374
- Registration Number
- NCT02117934
- Locations
- 🇺🇸
Clinical Research Advantage, Inc., Plano, Texas, United States
🇺🇸Radiant Research, Murray, Utah, United States
🇺🇸Clinical Research Advantage, Inc, Evansville, Indiana, United States
A Study of the Immune Response to Heplisav in Healthy Older Adults
- Conditions
- Hepatitis B
- Interventions
- Biological: HEPLISAV
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT01999699
- Locations
- 🇺🇸
Johnson County Clinical Trials, Lenexa, Kansas, United States